Dihydroorotate dehydrogenase · SINGLE PROTEIN · Plasmodium falciparum
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Dihydroorotate dehydrogenase shows clinical signal disease relevance led by Plasmodium falciparum malaria. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q54A96. Start with Plasmodium falciparum malaria, then reuse UniProt Q54A96 as the stable protein anchor across project notes and exports.
Start with Plasmodium falciparum malaria, then reuse UniProt Q54A96 as the stable protein anchor across project notes and exports.
Dihydroorotate dehydrogenase shows clinical signal disease relevance led by Plasmodium falciparum malaria. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with Plasmodium falciparum malaria because it currently carries clinical signal support. Linked drugs include DSM-265. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyDihydroorotate dehydrogenase (quinone), mitochondrial
Review this target as Dihydroorotate dehydrogenase, mapped to UniProt Q54A96. ChEMBL maps the protein component as Dihydroorotate dehydrogenase (quinone), mitochondrial. Sequence length is 569 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Dihydroorotate dehydrogenase as ChEMBL target CHEMBL3486, mapped to UniProt Q54A96. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Dihydroorotate dehydrogenase is the right protein anchor across sources, using UniProt Q54A96 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why Plasmodium falciparum malaria is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Dihydroorotate dehydrogenase |
| Target Type | SINGLE PROTEIN |
| Organism | Plasmodium falciparum |
| UniProt | Q54A96 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Dihydroorotate dehydrogenase (quinone), mitochondrial |
| UniProt Accession | Q54A96 |
| Component Type | Protein |
| Sequence Length | 569 aa |
Dihydroorotate dehydrogenase (quinone), mitochondrial
Review this target as Dihydroorotate dehydrogenase, mapped to UniProt Q54A96. ChEMBL maps the protein component as Dihydroorotate dehydrogenase (quinone), mitochondrial. Sequence length is 569 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Dihydroorotate dehydrogenase shows clinical signal disease relevance led by Plasmodium falciparum malaria. 2 more disease programs remain visible in the same review block.
Start review with Plasmodium falciparum malaria because it currently carries clinical signal support. Linked drugs include DSM-265. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL387254 | 8.61 | Ki | 2.45 | Preclinical |
| CHEMBL3289671 | 8.29 | Kd | 5.1 | Preclinical |
| CHEMBL2431496 | 8.22 | IC50 | 6.0 | Preclinical |
| CHEMBL3289672 | 8.02 | Kd | 9.6 | Preclinical |
| CHEMBL3289670 | 8.01 | Kd | 9.8 | Preclinical |
| CHEMBL1956285 | 8.0 | IC50 | 10.0 | Clinical |
| CHEMBL4545127 | 8.0 | IC50 | 10.0 | Preclinical |
| CHEMBL2012961 | 7.77 | IC50 | 17.0 | Preclinical |
| CHEMBL2431499 | 7.75 | IC50 | 18.0 | Preclinical |
| CHEMBL1956288 | 7.72 | IC50 | 19.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 22 | 188 | 6.1 |
| assay format | 10 | 192 | 6.1 |
| cell-based format | 1 | 7 | 7.1 |